Overview

Treatment Use of 3,4-Diaminopyridine

Status:
No longer available

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This protocol has provided 3,4 diaminopyridine (DAP) under a treatment-use IND to patients with congenital myasthenic syndrome (CMS). It is currently closed to enrollment.

Details

Lead Sponsor:

Vern C. Juel, M.D.

Treatments:

3,4-diaminopyridine
4-Aminopyridine
Amifampridine